547. Risk Factors Associated with 30-Day Mortality in a Large Cohort of Patients who Received Remdesivir and Corticosteroids for Severe COVID-19

BACKGROUND: Remdesivir (RDV), an antiviral agent, is approved by Food and Drug Administration (FDA) for the treatment of patients (pts) admitted with SARS-COV-2 infection (COVID-19). Earlier RDV studies (such as ACCT-1) prior to widespread use of corticosteroids (CS), showed a 30-day mortality of 11...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Kartik, Monday, Lea, Kaushik, Milan, Alangaden, George J, Brar, Indira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644644/
http://dx.doi.org/10.1093/ofid/ofab466.746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644644/
http://dx.doi.org/10.1093/ofid/ofab466.746

Ejemplares similares